--- title: "Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results" type: "News" locale: "en" url: "https://longbridge.com/en/news/295856128.md" description: "Telomir Pharmaceuticals (NASDAQ:TELO) reported quarterly earnings of ($0.79) per share. Shares fell $0.06 to $1.05 on Thursday with lower-than-average volume. The company has a market cap of $72.22 million. Several hedge funds, including Bank of America and Raymond James, increased their stakes in the fourth quarter. Weiss Ratings reiterated a 'sell' rating, while the average analyst rating remains 'Hold'." datetime: "2026-08-13T22:56:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295856128.md) - [en](https://longbridge.com/en/news/295856128.md) - [zh-HK](https://longbridge.com/zh-HK/news/295856128.md) generator: "portal-rs" --- # Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.79) earnings per share (EPS) for the quarter, Zacks reports. ## Telomir Pharmaceuticals Price Performance Shares of Telomir Pharmaceuticals stock traded down $0.06 during trading on Thursday, reaching $1.05. 86,652 shares of the stock traded hands, compared to its average volume of 126,949. The company has a market capitalization of $72.22 million, a price-to-earnings ratio of -3.62 and a beta of -0.24. The business has a fifty day simple moving average of $1.22 and a two-hundred day simple moving average of $1.26. Telomir Pharmaceuticals has a 52-week low of $0.89 and a 52-week high of $2.09. ## Hedge Funds Weigh In On Telomir Pharmaceuticals A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its holdings in Telomir Pharmaceuticals by 283.9% during the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company's stock valued at $61,000 after buying an additional 10,880 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Telomir Pharmaceuticals during the 2nd quarter worth approximately $33,000. XTX Topco Ltd bought a new position in shares of Telomir Pharmaceuticals during the 4th quarter valued at approximately $53,000. Jane Street Group LLC bought a new position in shares of Telomir Pharmaceuticals during the 2nd quarter valued at approximately $62,000. Finally, Raymond James Financial Inc. grew its holdings in shares of Telomir Pharmaceuticals by 4,101.9% in the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company's stock valued at $105,000 after purchasing an additional 73,547 shares in the last quarter. ## Analysts Set New Price Targets Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Telomir Pharmaceuticals in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold". **Read Our Latest Stock Analysis on Telomir Pharmaceuticals** ## Telomir Pharmaceuticals Company Profile (Get Free Report) Telomir Pharmaceuticals, Inc NASDAQ: TELO is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited. The company's lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling. ## See Also - Five stocks we like better than Telomir Pharmaceuticals - Asian Market Circuit Breakers Hit Stocks, Not AI Demand - Riot Platforms Re-Wires the Ledger for a $9B AI Power Play - Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy? - Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Telomir Pharmaceuticals Right Now? Before you consider Telomir Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telomir Pharmaceuticals wasn't on the list. While Telomir Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [TELO.US](https://longbridge.com/en/quote/TELO.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [RJF.US](https://longbridge.com/en/quote/RJF.US.md) - [RIOT.US](https://longbridge.com/en/quote/RIOT.US.md) - [NBIS.US](https://longbridge.com/en/quote/NBIS.US.md) - [JOBY.US](https://longbridge.com/en/quote/JOBY.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) - [RJF-B.US](https://longbridge.com/en/quote/RJF-B.US.md) - [JOBY+.US](https://longbridge.com/en/quote/JOBY+.US.md) ## Related News & Research - [Raymond James Financial (RJF) Gets a Hold from TD Cowen](https://longbridge.com/en/news/297645761.md) - [BUZZ-Truist initiates Raymond James with 'hold'](https://longbridge.com/en/news/297655143.md) - [Is American Express Stock Underperforming the Nasdaq?](https://longbridge.com/en/news/297526158.md) - [Is Danaher Stock Underperforming the Nasdaq?](https://longbridge.com/en/news/297534288.md) - [Is Analog Devices Stock Outperforming the Nasdaq?](https://longbridge.com/en/news/297807248.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**